)
)
)
LPOXY Therapeutics
LPOXY Therapeutics is a clinical-stage biopharmaceutical company developing SIDIPREV™, a first-in-class oral preventive for Clostridioides difficile infection (CDI). SIDIPREV™ is designed to prevent CDI in hospitalized adults receiving high-risk antibiotics, addressing a major unmet need in infection prevention. The company’s planned registration trial, STOP-Cdiff, will be conducted under the FDA’s LPAD pathway guidance. LPOXY holds an extensive global patent portfolio supporting SIDIPREV™’s development and market exclusivity. The company is completing formation of its Series A investor syndicate to fund the SIDIPREV™ registration program and welcomes engagement from institutional investors, family offices, and strategic partners aligned with hospital-based infection prevention.
Address
Platte CityMissouri
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)